These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 22824792)

  • 1. Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors.
    Bagci-Onder T; Agarwal A; Flusberg D; Wanningen S; Sorger P; Shah K
    Oncogene; 2013 Jun; 32(23):2818-27. PubMed ID: 22824792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomas.
    Nesterenko I; Wanningen S; Bagci-Onder T; Anderegg M; Shah K
    PLoS One; 2012; 7(11):e49219. PubMed ID: 23145127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
    Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS
    Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL.
    Aguilera DG; Das CM; Sinnappah-Kang ND; Joyce C; Taylor PH; Wen S; Hasselblatt M; Paulus W; Fuller G; Wolff JE; Gopalakrishnan V
    J Neurooncol; 2009 Jul; 93(3):303-18. PubMed ID: 19148581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors.
    Redjal N; Zhu Y; Shah K
    Stem Cells; 2015 Jan; 33(1):101-10. PubMed ID: 25186100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo.
    Srivastava RK; Kurzrock R; Shankar S
    Mol Cancer Ther; 2010 Dec; 9(12):3254-66. PubMed ID: 21041383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors.
    Phillips DC; Buchanan FG; Cheng D; Solomon LR; Xiao Y; Xue J; Tahir SK; Smith ML; Zhang H; Widomski D; Abraham VC; Xu N; Liu Z; Zhou L; DiGiammarino E; Lu X; Rudra-Ganguly N; Trela B; Morgan-Lappe SE
    Cancer Res; 2021 Jun; 81(12):3402-3414. PubMed ID: 33687950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
    Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
    Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor-related apoptosis-inducing ligand and induces an alternative cell death pathway.
    Badr CE; Wurdinger T; Nilsson J; Niers JM; Whalen M; Degterev A; Tannous BA
    Neuro Oncol; 2011 Nov; 13(11):1213-24. PubMed ID: 21757445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. microRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis.
    Bhere D; Tamura K; Wakimoto H; Choi SH; Purow B; Debatisse J; Shah K
    Neuro Oncol; 2018 Jan; 20(2):215-224. PubMed ID: 29016934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma.
    Karpel-Massler G; Pareja F; Aimé P; Shu C; Chau L; Westhoff MA; Halatsch ME; Crary JF; Canoll P; Siegelin MD
    PLoS One; 2014; 9(12):e114583. PubMed ID: 25531448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5.
    Di X; Zhang G; Zhang Y; Takeda K; Rivera Rosado LA; Zhang B
    Oncotarget; 2013 Sep; 4(9):1349-64. PubMed ID: 23988408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming TRAIL Resistance for Glioblastoma Treatment.
    Deng L; Zhai X; Liang P; Cui H
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33919846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin-dependent upregulation of death receptors 4 and 5 augments induction of apoptosis by TNF-related apoptosis-inducing ligand against esophageal squamous cell carcinoma.
    Kondo K; Yamasaki S; Sugie T; Teratani N; Kan T; Imamura M; Shimada Y
    Int J Cancer; 2006 Jan; 118(1):230-42. PubMed ID: 16003725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IFN‑β sensitizes TRAIL‑induced apoptosis by upregulation of death receptor 5 in malignant glioma cells.
    Yoshimura S; Sano E; Hanashima Y; Yamamuro S; Sumi K; Ueda T; Nakayama T; Hara H; Yoshino A; Katayama Y
    Oncol Rep; 2019 Dec; 42(6):2635-2643. PubMed ID: 31638255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors.
    Oh Y; Swierczewska M; Kim TH; Lim SM; Eom HN; Park JH; Na DH; Kim K; Lee KC; Pomper MG; Lee S
    J Control Release; 2015 Dec; 220(Pt B):671-81. PubMed ID: 26381901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tanshinone IIA sensitizes TRAIL-induced apoptosis in glioblastoma through inducing the expression of death receptors (and suppressing STAT3 activation).
    Zhou X; Lv L; Tan Y; Zhang Z; Wei S; Xiao S
    Brain Res; 2021 Sep; 1766():147515. PubMed ID: 33984327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects.
    van de Water JA; Bagci-Onder T; Agarwal AS; Wakimoto H; Roovers RC; Zhu Y; Kasmieh R; Bhere D; Van Bergen en Henegouwen PM; Shah K
    Proc Natl Acad Sci U S A; 2012 Oct; 109(41):16642-7. PubMed ID: 23012408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.
    Häcker S; Dittrich A; Mohr A; Schweitzer T; Rutkowski S; Krauss J; Debatin KM; Fulda S
    Oncogene; 2009 Sep; 28(35):3097-110. PubMed ID: 19597472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction.
    Eramo A; Pallini R; Lotti F; Sette G; Patti M; Bartucci M; Ricci-Vitiani L; Signore M; Stassi G; Larocca LM; Crinò L; Peschle C; De Maria R
    Cancer Res; 2005 Dec; 65(24):11469-77. PubMed ID: 16357155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.